News & Updates

People with less healthy lifestyles appear to obtain greater protection against colorectal cancer (CRC) with aspirin use, according to a study.

Virally suppressed adolescents living with HIV-1 who switched from daily oral to long-acting (LA) injectable cabotegravir (CAB) plus rilpivirine (RPV) every 8 weeks show an acceptable safety profile, with pharmacokinetics similar to adults, according to the week-48 results of the IMPAACT 2017 study.

More than one-fifth of patients with acute cerebral ischaemia (ACI) appear to be receiving statins unnecessarily, which has the potential to cause higher than 5,600 adverse events (AEs) each year, including diabetes, myopathy, and eye disease, according to the results of a meta-analysis.

New drug applications approved by US FDA as of 16-31 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In the treatment of women with endometriosis-associated pain, relugolix combination has a risk-benefit profile that is more favourable than that of monotherapy, due to the latter contributing to increased vasomotor symptoms and substantial bone mineral density (BMD) loss, as shown in a study.

Daily intake of 100-mg aspirin over 3 years does not appear to limit the progression of age-related hearing loss, according to a secondary analysis of the ASPREE study.